New Evidence Links APS Antibodies to Severe Mental Illness – Thrombosis Update
Thrombosis Update shared a post on LinkedIn about a paper by Silvia Hoirisch-Clapauch and Antonio E. Nardi:
“New article in Thrombosis Update
Researchers have found that specific antiphospholipid antibody (APLA) profiles dramatically increase the risk of severe mental illness (SMI) in patients with primary APS.
A long-term case-control study suggests that individuals with multiple or high-titer APLA are at a seven to 21-fold increased risk of developing psychosis, severe depression, and/or high impulsivity. The findings support the hypothesis that autoimmunity plays a significant role in severe mental disorders.
This work highlights the need for:
- Routine mental health screening in high-risk APS patients.
- Further research into antibody-reduction protocols as a potential new intervention for treatment-resistant SMI
Lucy Norris TruJournal
Read more here.”
Title: Primary antiphospholipid syndrome and severe mental illness: preliminary results of a long-term case-control study
Authors: Silvia Hoirisch-Clapauch and Antonio E. Nardi

-
Oct 29, 2026, 16:22Aysha O’Connor: One of the Hardest Parts of My Own Fertility Journey Was Loneliness…
-
Oct 29, 2026, 16:15Chaithra S K: Preimplantation Genetic Testing Still Requires an Embryo Biopsy
-
Oct 29, 2026, 16:11Filipina Woman’s Journey of Strength, Hope, and Finding Balance While Living with PCOS – PCOS Millennials
-
Oct 29, 2026, 15:58Eric Lameignere: Can DNA Fragmentation in Cumulus Cells Predict ICSI Outcomes?
-
Oct 29, 2026, 15:50Saadat Hassan: Sperm Function Testing – Can Advanced Diagnostics Guide IVF and ICSI Selection?
-
Oct 29, 2026, 15:34Sara Spiro: Celebrating the Stories Members Have Trusted With at Maven Clinic – Here Is Mine
-
Oct 29, 2026, 15:31Dina Ibrahem: 0 Motility, 1 Critical Decision
-
Oct 29, 2026, 15:28AI and Automation in Fertility and Genomics: Pipeline or Pipe Dream? – ARCS
-
Oct 29, 2026, 15:26Michael Schindler: Large Networks or Small Centers – Who Delivers Better Care?
